ATEM Capital Fund LP
ATEM Capital is a New York-based venture capital firm founded in 2014 that specializes in early, late-stage, and growth capital investments within the life sciences sector. The firm primarily targets the biotechnology and pharmaceuticals fields, allocating 70% of its investments to these areas, which includes a focus on early-stage and late-stage assets. Additionally, it invests in de-risked medical devices and diagnostics, accounting for the remaining 30% of its portfolio. ATEM Capital is particularly interested in life-saving and life-changing technologies, including those related to oncology, cardiovascular health, anti-infectives, CNS/pain management, and women's health. The firm focuses its investment efforts in the United States and Western Europe, targeting companies with market capitalizations under $300 million and listed on major stock exchanges. ATEM Capital also engages in direct co-investments.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
7 past transactions
PGxAI
Seed Round in 2025
PGxAI is an AI-powered pharmacogenetics platform enabling precision medicine by applying proprietary algorithms to real-world data to inform drug choice, dosing personalization, and drug-drug interaction identification. It partners with InterSystems, a major patient-data provider, and uses tools such as VectorSearch and GenAI to access extensive real-world data. The platform supports clinical decision-making, aims to improve patient outcomes, accelerate drug development, and reduce costs through targeted patient stratification and real-time analytics. It delivers rapid, actionable reports via seamless LIMS integration, enabling healthcare organizations to implement personalized medicine at scale.
YCare
Seed Round in 2024
YCare specializes in remote health monitoring systems. Its platform integrates with wearables, medical devices, EHRs, and healthcare management systems to collect real-time patient data, enabling clinicians to make informed decisions.
PGxCare
Seed Round in 2024
PGxCare offers an AI capabilities, enabling analysis of pharmacogenetic data ensuring accurate results tailored to individual needs.
Walden Biosciences
Series B in 2023
Walden Biosciences, Inc. is a biotechnology company dedicated to developing innovative treatments for individuals suffering from kidney diseases, including chronic kidney disease and acute kidney injury. Founded in 2013 and based in Cambridge, Massachusetts, the company focuses on targeting specific biological mechanisms related to renal health. It specializes in therapies that address suPAR, an inflammatory biomarker linked to kidney function, and Dynamin, an enzyme crucial for maintaining podocyte integrity. By applying a systems-based approach, Walden Biosciences aims to transform the therapeutic landscape for kidney disease, offering targeted treatment options that address both rare and prevalent conditions affecting kidney health.
DEKA Biosciences
Series B in 2023
DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.
Triumvira Immunologics
Series A in 2022
Triumvira Immunologics USA, Inc. is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies aimed at improving cancer treatment outcomes. Its primary offerings include chimeric antigen receptor (CAR) therapies and engineered T cell receptor (TCR) therapies. A key aspect of Triumvira's approach is its proprietary T cell Antigen Coupler (TAC) technology, which recruits the entire natural T cell receptor and operates independently of the major histocompatibility complex (MHC). This technology enables the development of more effective therapies for a wider array of patients suffering from both solid and liquid malignancies, as well as other diseases beyond cancer.
Iridia
Series B in 2021
Iridia, Inc. is a nanotechnology company based in Carlsbad, California, specializing in innovative data storage solutions utilizing DNA. Founded in 2016, Iridia has developed a pioneering DNA-based data storage system that integrates DNA polymer synthesis technology with semiconductor fabrication and electronic nano-switches. This technology allows for the writing, storing, and reading of data in a highly efficient manner, significantly reducing infrastructure requirements and environmental impact. By employing a highly-parallel format, Iridia's solution offers the potential for exceptionally high-density data storage, making it a commercially attractive option for managing large volumes of data. Formerly known as Dodo OmniData, Inc., the company rebranded to Iridia, Inc. in March 2018.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.